Although some genomic events occur with high frequency (e.g. TERT promoter mutations in > 75% of cases, TP53 mutations in c.50%), MIBCs are heterogeneous and characterised by a large number of single nucleotide variants (SNVs) and copy number variants (CNVs) [2, 3]; loss of multiple tumour suppressors and alteration of multiple pathways are common. Here, TP53 is linked to neoplasm.